InsidersTradesSigma
Follow the Butterfly Network, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Butterfly Network, Inc. has logged 231 insider filings. Market capitalisation: €2.4bn. The latest transaction was filed on 25 August 2026 (Don). Among the most active insiders: ROTHBERG JONATHAN M. The full history is openly available.
231
Insider Decl.
n/a
Thresholds
€10m
12 ops.
Buy Volume
€99m
106 ops.
Sell Volume
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,239 of 28,899 companies
27.7
score / 100
Value30
Quality26
FCF yld-0.7%
Earn yld-3.2%
EV/EBITDA·
ROE-35%
Gross mgn47%
Net mgn-79%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations231 total
250,000 shares0Class A Common StockSEC:0002064832-26-000280:0
215,233 shares@ US$9.54180.088% mcap3.5% of flowClass A Common StockSEC:0000905148-26-003784:0
500,000 shares@ US$9.23550.20% mcap8.0% of flowClass A Common StockSEC:0000905148-26-003784:1
175,300 shares@ US$8.86040.066% mcap2.7% of flowClass A Common StockSEC:0000905148-26-003784:2
824,700 shares@ US$8.69730.31% mcap12.4% of flowClass A Common StockSEC:0000905148-26-003784:3
582,500 shares@ US$8.97020.22% mcap9.0% of flowClass A Common StockSEC:0000905148-26-003784:4
115,200 shares@ US$8.67630.043% mcap59.4% of flowClass A Common StockSEC:0002064832-26-000274:0
Canonical exit: 12 Nov 2026 (T+90)
10,000 shares@ US$9.750.0039% mcap43.8% of flowClass A Common StockSEC:0002064832-26-000270:0
68,346 shares@ US$10.0090.027% mcap6.3% of flowClass A Common StockSEC:0002064832-26-000268:0
10,000 shares@ US$9.750.0039% mcap78.0% of flowClass ASEC144:0001959173-26-005883
68,346 shares@ US$10.00910.029% mcap6.7% of flowClass ASEC144:0001959173-26-005846
8,770 shares@ US$9.75050.0036% mcap3.1% of flowCommon StockSEC144:0001964306-26-000375
68,852 shares@ US$7.8630.025% mcap30.6% of flowClass A Common StockSEC:0002064832-26-000264:0
1,720,129 shares@ US$7.39250.53% mcap34.1% of flowClass A Common StockSEC:0000905148-26-003455:0
156,163 shares@ US$8.10480.053% mcap3.4% of flowClass A Common StockSEC:0000905148-26-003455:1
1,876,292 shares@ US$7.110.55% mcap57.2% of flowClass A Common StockSEC144:0000905148-26-003437
68,852 shares@ US$7.86330.022% mcap44.2% of flowClass ASEC144:0001959173-26-005477
72,724 shares@ US$6.46980.020% mcap0.4% of flowClass B Common StockSEC:0001104659-26-086681:1
54,143 shares@ US$6.46980.015% mcap0.3% of flowClass B Common StockSEC:0001104659-26-086681:0
496,680 shares@ US$6.46980.13% mcap2.7% of flowClass B Common StockSEC:0001104659-26-086681:2
36,366 shares@ US$6.46980.0099% mcap0.2% of flowClass B Common StockSEC:0001104659-26-086681:3
659,913 shares@ US$6.47050.18% mcap3.8% of flowClass A CommonSEC144:0001974158-26-000088
753,320 shares@ US$6.73020.21% mcap4.6% of flowClass A CommonSEC144:0001974158-26-000087
1,195,857 shares@ US$6.59590.33% mcap7.6% of flowClass B Common StockSEC:0001104659-26-085497:0
753,320 shares@ US$6.73590.21% mcap4.9% of flowClass B Common StockSEC:0001104659-26-085497:2
25 of 231 declarations
About Butterfly Network, Inc.
Butterfly Network, Inc. is a U.S.-based medical technology company listed on the NYSE under the ticker BFLY in the United States market. Founded in 2011 by Dr. Jonathan Rothberg, the company was built around a clear mission: democratize medical imaging by making ultrasound more affordable, portable, easier to use, and more widely accessible. Its headquarters are in Burlington, Massachusetts, and it has a commercial footprint that spans the United States and multiple international markets. For French-speaking investors, Butterfly is best viewed as a growth-stage medtech with a still-evolving commercial model and a meaningful execution story ahead. The business centers on semiconductor-based handheld ultrasound devices, cloud software, and AI-enabled workflows. Butterfly’s core product family includes Butterfly iQ, iQ+, and the third-generation iQ3, all designed to bring whole-body point-of-care ultrasound into a compact, smartphone- and tablet-connected format. The company also offers Butterfly Move, which combines portability with cart-like stability, and more specialized solutions such as iQ+ Bladder. Beyond hardware, Butterfly is working to expand recurring revenue through software subscriptions, cloud-connected services, and ecosystem monetization via initiatives such as Butterfly Embedded and Butterfly Garden. From a competitive standpoint, Butterfly Network targets the point-of-care ultrasound (POCUS) market, where adoption depends on device simplicity, workflow integration, clinical utility, and total cost of ownership. Its differentiation lies in its ultrasound-on-chip architecture, software-led product design, and a platform approach that can extend beyond traditional device sales. That makes Butterfly a distinct competitor versus larger, more established imaging vendors that rely on conventional ultrasound hardware. The company is pushing deeper into hospitals, outpatient settings, community care, and home-based use cases, which broadens its long-term addressable market. Recent developments reinforce that strategic direction. Butterfly launched the iQ3 in the U.S. in 2024 and expanded it into Europe the same year. In 2026, the company announced its first FDA clearance for a blind-sweep ultrasound AI tool, underscoring its push into AI-enabled imaging. More recently, Butterfly reported accelerating revenue growth in 2025 and early 2026, alongside progress on HomeCare commercialization and growing contributions from licensing and partnership revenue. In short, Butterfly Network remains a transformation story in digital health and ultrasound: attractive for its technology and platform potential, but still dependent on commercial execution, regulatory milestones, and its ability to scale adoption against strong competition.
